Journey Medical Corporation

Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to Journey Medical's full-year 2025 financial results and corporate update conference call. At this time, all participants are in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. As a webcast replay of this call will be available approximately one hour after the end of the call for approximately 30 days. I would now like to turn the conference call over to Jacqueline Jaffe, the company's Senior Director of Corporate Operations. Please go ahead, Jacqueline.

Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Morali, Co-Founder, President, and Chief Executive Officer, Joseph Binesh, Chief Financial Officer, and Ramzi Aloush, Chief Operating Officer and General Counsel. During this call, management will be making forward-looking statements, including statements that address, among other things, Journey Medical's expectations for future performance, operational results, financial condition, and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q, the Form 8-K files of the SEC today, and the company's press release that accompanies this call, particularly the cautionary statements in it. Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP. For reconciliation of this non-GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company's earnings press release. The content of this call contains time-sensitive information that is accurate only as of today, Wednesday, March 25th, 2026. Except as required by law, Journey Medical disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Claude Morali, co-founder, president, and chief executive officer of Journey Medical.

Thank you, Jacqueline, and good afternoon to everyone on the call today. 2025 was a milestone year for Journey Medical, as we successfully launched MROSI, our internally developed, best-in-class oral treatment for the inflammatory lesions of rosacea. MROSI was made available to pharmacies in late March of last year, and our promotional activities began in early April. I am pleased to report that during the three quarters of 2025 in which Amrosi was commercially available, the product achieved 14.7 million in net sales. With regard to our full year 2025 performance, we delivered total net product revenue growth of 11%, and we improved our gross margin by nearly 3.5 percentage points compared to the 2024 period. Importantly, our business was able to make solid financial progress despite pressure on our Accutane franchise and other legacy products due to generic competition. With regards to our focus on improving profitability of the business, I am pleased to report that we generated positive adjusted EBITDA as well as positive EBITDA in the fourth quarter of 2025. Given our expectation for continued sales growth and additional leverage from our established commercial sales organization, we expect to remain adjusted EBITDA positive in 2026 and the foreseeable future. With our solid cash position of approximately $24 million, I believe that Journey is well positioned to execute on our business plan and grow sales and profitability with the resources that we have in place. One of the key highlights for 2025 is the strong prescription volume that we generated with Ambrosie. Total Ambrosie prescriptions were approximately 53,000 since promotion began in April of last year, which we believe is a very strong start. In the fourth quarter alone, Total prescription volume for MROSI grew nearly 50% sequentially compared to the third quarter last year, and growth is continuing in Q1 of this year. Our sales organization continues to promote the superior efficacy of MROSI compared to the only other branded oral rosacea treatment, Oracea, in addition to MROSI's placebo-like safety and tolerability profile. Notably, the extremely positive head-to-head results against aurasia and placebo in Ambrosie's Phase III clinical trials are playing out in the real world. Physician feedback continues to be very positive, and the rising refill rate for Ambrosie continues to demonstrate that patients are pleased with the results. Ambrosie's superior efficacy and rapid onset of action compared to aurasia with effects seen in as little as two weeks, are key benefits that we believe are supporting the demand and patient refill behavior. Along with the high satisfaction rate that we are seeing with our current customers, we continue to expand adoption of MROSI in more dermatology practices. We ended 2025 with approximately 3,200 unique prescribers of MROSI, reaching our initial goal of prescribers in the top deciles that routinely write for a ratio and similar products. While we were able to meet our initial prescriber target quite rapidly, we continue to increase this number, and today we are disclosing that over 3,500 unique dermatology prescribers have now written at least one script for Amrosi. I'll now provide some additional color on our managed care and market access progress firm, ROSI, as this is an important component of the value inflection that we expect in 2026. Prescription demand continues to track ahead of reported revenue. That dynamic is primarily driven by the timing of downstream health plan coverage decisions and formulary implementation cycles. which are progressing as expected for a newly launched branded dermatology product. At present, approximately 100 million commercial covered lives have access to MROSI. This includes contracts in place with two of the top three group purchasing organizations in the United States. These agreements provide the framework for broader downstream payer adoption as individual health plans complete their internal review and P&T processes. As we mentioned on our third quarter earnings call, we anticipate contracting with the third major GPO by late Q1 or early Q2 of this year, and we remain on track to meet this objective. Importantly, We are not solely focused on breadth of coverage, but also the quality of coverage, including tier positioning, step edit requirements, and prior authorization criteria to ensure that the value of OMROSI's differentiated clinical profile is appropriately recognized. As coverage expands and formulary policies mature throughout 2026, we expect to see improved reimbursement rates, reduced reliance on our co-pay bridging program, and an increase in Ambrosie sales and overall operating margin expansion. Our sales professionals continue to focus on building new prescription demand for Ambrosie, as we believe it is important to broadly develop positive physician and patient experiences with the brand. In addition, critical mass and prescription volume also factors into the evaluation of reimbursement and pricing policies with the downstream health plans. Along with the strong prescription demand, our market access discussions are supported by several important clinical and publication milestones. These are MROSI's head-to-head superiority data versus Oratia, the publication of MROSI's Phase III efficacy and safety results in JAMA dermatology, and the updated treatment algorithms from the National Rosacea Society. These third-party validations are meaningful in payer evaluations, particularly as plans assess clinical differentiation and long-term health economic impact. We believe that MROSI's rapid onset of action placebo-like tolerability, and superior facial clearing and lesion reduction profile position it well for continued formulary inclusions. As these initiatives materialize, we expect a meaningful inflection in revenue conversion relative to prescription demand. While we have commented on our expectations for positive EBITDA this year, We plan to offer more detailed financial guidance later in the year once we have better clarity on the downstream health plan adoption of MROSI. I mentioned earlier that MROSI's positive phase three clinical trial results were published in JAMA Dermatology and that the National Rosacea Society updated their treatment algorithms, highlighting MROSI's position as an effective therapy for rosacea treatment. Both of these publications were issued in the first half of 2025 and support Ambrosie's superior clinical efficacy in treating rosacea, its favorable safety profile, and the product's convenient once-daily oral dosing. This year, we expect to announce up to three new journal publications on Ambrosie. We also believe that MROSI has potential to be incorporated into the consensus treatment guidelines for rosacea, which should support further market and health plan adoption. In addition, we remain active at key dermatology medical conferences across the United States to build awareness and momentum behind the MROSI brand. Last year, we presented clinical data at two medical conferences. the Society of Dermatology Physicians Associates Summer Conference in June, and the 2025 Fall Clinical Dermatology Conference in October. We plan to attend an exhibit at this year's American Academy of Dermatology meeting at the end of this month, where we kicked off from ROSI's launch last year. Given the market penetration that we have achieved so far with rosacea prescribers, We believe that this large-scale conference will help us further increase brand awareness and prescriber adoption of MROSI. Additionally, we expect to exhibit and potentially present a clinical data later this year at other dermatology conferences. With regard to our broader product offering, we plan to launch one or two additional incremental dermatology products later this year. We believe that the launch of these products can also benefit from our dermatology conference presence in addition to direct promotion by our sales organization. And with that, I'll turn the call over to our CFO, Joe Benesch, to review our 2025 financial results.

Thank you, Clyde. Good afternoon to everyone. I will now walk you through our financial results for the full year 2025. Total revenues for the year were $61.9 million, representing a 10% increase compared to $56.1 million for 2024. The increase reflects incremental net product revenue related to the successful U.S. commercial launch of Ambrosie. Turning to margins. Gross margin for 2025 was 66.2% compared to 62.8% in 2024. The improvement reflects a favorable product mix with higher margin contributions from Enrose EQ Brexa, along with lower overall inventory period costs. SG&A expenses totaled $44.4 million for 2025, up approximately 10% from $40.2 million to 2024. This increase reflects additional operating activities to support the launch and continued expansion of EMROSI. We reported a gap net loss of $11.4 million, with 47 cents per share basic and diluted for 2025, compared to a gap net loss of $14.7 million, or 72 cents per share, in 2024. On a non-GAAP basis, both EBITDA and adjusted EBITDA improved year over year. EBITDA improved by $5.2 million, narrowing from a loss of $9.2 million in 2024 to a loss of $4 million in 2025. Adjusted EBITDA was a positive $2.9 million for the full year 2025 compared to $800,000 in 2024, reflecting further progress towards our goal of sustainable profitability. We ended the year with $24.1 million in cash compared to $20.3 million at December 31, 2024. Working capital at year end was $29.4 million, up from $13 million a year ago, an increase of $16.4 million. In summary, we delivered a year of strong execution, We achieved year-over-year revenue growth driven primarily by the launch and uptake of MROSI, improved gross margins versus the prior year, reflecting a more favorable product mix and operating leverage, resulting in narrow net losses and positive adjusted EBITDA. Importantly, we closed 2025 with a healthy cash position that we believe supports our ongoing operations and commercial growth into the foreseeable future. Looking ahead, We remain focused on discipline expense management and margin expansion as we continue to scale Amrosi's commercial footprint and strengthen our product portfolio. This focus, we believe we are well positioned to deliver improved and sustainable profitability over the upcoming quarters. Thank you very much. I will now turn the call back over to Claude.

Thank you, Joe. To summarize, 2025 was a transformational year for Journey Medical, as Amrosi had a strong market debut and became our flagship commercial product. We generated approximately 53,000 total prescriptions for Amrosi in 2025 after launching the product in April. And scripts continue to show strong sequential growth as we head toward the product's first year on the market. Notably, The run rate for Amrosi total prescriptions exiting 2025 calculates to over 126,000 annually. We are continuing to expand the base of unique prescribers for Amrosi after meeting our initial goal of 3,200 dermatology writers in 2025. With approximately 15,000 dermatologists in the U.S., 17 million Americans suffering from rosacea, and over 6 million rosacea prescriptions written in 2025, we believe there is significant room for Ambrosie to grow and become a leading dermatology brand. Importantly, the growing base of Ambrosie prescribers enables more and more patients to experience Ambrosie's best-in-class efficacy and rapid onset of action relative to Oratia, the only other branded oral rosacea treatment. In the third quarter, we saw approximately one refill for every new prescription written for Amrosi. And at the end of 2025, the ratio was at 1.4 refills to each new prescription. Given the chronic nature of rosacea, characterized by frequent episodes of relapse, the long-term value of each rosacea patient can be significant to our business. We believe the prescription trends so far demonstrate that we are making good progress and that initial patient experiences are converting into long-term brand loyalty. As a result, we expect the ratio of refills to new MROSI prescriptions to continue to grow. While our base business came under some pressure last year due to competitive challenges, we continue to grow our sales, expand our gross margin, and we achieved our objective of becoming EBITDA positive exiting 2025. In 2026, we expect to continue improving upon the financial performance as adoption of Ambrosie grows, downstream health plan coverage increases, and Ambrosie sales accelerate and track more closely with prescription growth trends. While we focus on building the Ambrosie franchise, We also plan to launch up to two niche dermatology products this year to augment our base business and our revenue growth. We believe that this year we will demonstrate the leverage that we have in our business given our established dermatology commercial infrastructure and MROSI significant growth potential. And with our solid balance sheet, we believe that we are in a strong position to deliver on our business plan and execute on our core objectives which are as follows, to improve the lives of patients, offer dermatology healthcare providers innovative treatment options, and create long-term value for our shareholders. Thank you. Operator, we are now ready to open the lines for Q&A.

Thank you. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the key. If at any time your question has been addressed and you'd like to withdraw your question, please press star then two. First question comes from Scott Henry with Alliance Global Partners. Please go ahead.

Thank you and good afternoon. A lot of progress and certainly, you know, profitability is a huge accomplishment. So congratulations for that. I did just want to dig in a little bit on the MROSI prescriptions. I guess first, just the trends. Q1's been kind of flattish, but, you know, it did kind of kick up in December. So I don't know if some people bought ahead of time and the trends just taking time to flow out. Obviously, the copays reset. I just want to get your thoughts on Q1 prescriptions. And more importantly, do you think you've kind of finally got back up to a steady state where we should expect growth on a weekly basis? Thank you.

Yeah. Hi, Scott. Good afternoon. So thanks for the question. Yeah, I think, you know, as we leave Q4 and enter Q1, as you mentioned, there certainly is the new insurance deductible resets. So that typically will slow patient visits to their doctor. I think you add that as well to the severe storms up and down the East Coast. They were pretty brutal and severe. I think that's a factor as well. And then overall, even in February, you've got shorter months. And so all of these compounded, it's hard to really compare Q4, which typically would be one of the strongest quarters, to Q1 as a reset. I can tell you, like you also just mentioned, March has come back in very strong. And we still anticipate and expect that our Q1 total prescriptions will surpass our Q4 number. So we haven't lost any steam at all, and we continue to expect substantial growth with Ambrosie moving forward.

And do you feel that sequentially your momentum is building, so Q2 should be well stronger than Q1? Is that your kind of internal feel at this point in time?

Yeah, you're going to see a nice build in momentum with this. Again, If you think about it, 53,000 scripts in just nine months. When we look at Q4 with the 27,000 annualized, you're looking at 126,000 scripts for the year. And we certainly expect to be well past that overall. So we've got momentum on our side. This is a phenomenal message. The efficacy is established. We have superiority against Horatia. We're focused on Horatia. And, you know, the fact that it has, Ambrosie has rapid onset, not only, you know, as early as two weeks, Scott, but we work in half the time that Horatia does. So in eight weeks, we are equivalent to oratia in 16 weeks of therapy. So that really catches the attention of HCPs and dermatologists, and the fact that we have this great proprietary formulation, the lowest strength minocycline on the market, 25% immediate release, 75% extended release, so we call it modified minocycline, release, and it's really working well. It's offering safety-like placebo side effects. So I think all of that together is really good. I will add one more thing. We are planning to increase our sales force in single digits here, and that should be ramped up no later than the first part of So, we'll also have extra people on the ground across the states.

Okay. And just one more question, which is a little bit in the weeds. The challenge in predicting revenue for any quarter is heavily dependent on how much revenue comes in per script, which can be a function of inventory and many other things. i think q2 it was about 380 which was a big inventory build so we had a lot higher number q3 was using my numbers was about 270 which is i think where we thought it would kind of stay because that's around where you would expect with a gross to net adjustment but q4 it came in at closer to 180 so a lot lower revenue per script so you know kind of three questions go into that one Why do you think it is? Is that the copay? Is there something unique that happened? Two, where do you think it goes to in terms of is 270 still an achievable target? And three, you know, when do we think we get to that steady state? Revenue per script, hard to predict in the short term, but easier to predict in the long term. Just so any call you could give there would be appreciated.

Sure. Yeah, absolutely. So, you know, using your methodology in terms of calculating what the script level was for Q4. I believe you mentioned 180. That is not a good indicator in terms of our long-term net pricing, and certainly I would not use that number there. You know, as we look at the progress we've made throughout the year and The first quarter was Q2 for us commercially when we launched. We had about 7,000 plus prescriptions. We moved that up in Q3 up to 18,000 prescriptions. And then, you know, we hit 27,000 prescriptions in Q4 to close out the year. So, you know, the commercial team and the marketing team have done an excellent job going out there and getting adoption and so forth with acceptance with our physician base. And it's really provided very good patient experiences that dermatologists are seeing. So we've really accelerated the ramp on the prescriptions. And what you're really seeing is simply a function of reimbursement. So the mix of reimbursed prescriptions and those that come under our co-pay bridging program were, you know, more in proportion of the scripts were not being reimbursed and therefore hit our co-pay assistance program. So that's really what you see there in 2026. You know, we've said that we've signed up two of the three top GPOs. We expect the third GPO here to come on board imminently. So that's a good positive for us. And again, reimbursement will change that mix and that gross to net. Also, I would tell you that, you know, with the launch in April and our one year anniversary coming up, a lot of the plans have the new to market block or the new to market moratorium. And that will be lifted and allow us to have, again, more impact as we move through 2026. So, you know, we believe coverage is going to come on this year, and it's going to be a breakthrough year for Amrosi for sales as well as profitability. So that growth to net has a lot of upward pressure on it.

Okay, great. Thank you for the caller, and thank you for taking questions. Sure.

The next question comes from Mayank Mamdani with B-Radley Securities. Please go ahead.

Yes, good afternoon. Thank you for taking our questions. On the last point, Claude, on the gross net with, you know, two of three GPOs coming on board and the third, you know, imminently also coming on board, can you maybe just give us a little bit more color like you did on your earlier expectation Again, I understand you may not give us revenue guidance, but you gave us a script volume expectation for this year relative to what you analyzed in the fourth quarter. What is sort of your base case close to net for this year now that you're sort of going to get past the one-year mark? It would be helpful if you can maybe bracket something quantitatively.

Sure. So I guess two parts to your question. In terms of managed care and healthcare plans, I'm going to have Ramzi Alush, our Chief Operating Officer, jump in and give you some background on that.

Yeah, sure, Mike. And just to briefly answer your question, we expect, I'm not going to speak really quantitatively, but we do expect improvement. Patrick Barrett- Throughout 2026 gradual quarter over quarter. And as we hit certain milestones with natural national formularies and getting adoption for Rosie to become a covered drug on formulary Patrick Barrett- We expect again incremental gain in terms of gross to net, you know, the first year of any launch as Claude mentioned Patrick Barrett- You're typically going to have new to block new to market block and and these moratorium is where payers and plans are really going to want to see the drug play out. They're going to want to see how it's looking in the real world, what demand looks like, and they want to assess it financially as well. So our first 12 months was really focused on what we like to call phase one, which is the GPO contracting. And we contracted with the two largest in 2025 with the third year to come on board. And that really grants us, if you will, access, which is really the framework, the universe of commercial lives, which once we signed this third GPO, we'll have access to over 150 commercial lives. Now, access and coverage are two different things, right? Access is the framework, coverage we define a little bit more narrowly. Coverage is where you have these national plans that can now adopt under the GPO contracts and actually do. And what we like to consider a frictionless type of a transaction where you're likely to get a patient to adjudicate all the way through to a prescription is what we call quality coverage. And that's a single step therapy or through any oral and potentially any or any topical or not a double step, but a single step through either one of those. And so now that we've reached sort of that one year anniversary mark, We've already sort of preempted in terms of these national formularies that we're having discussions with. We have continued negotiations, continued clinical. I think from the clinical side, it's a no-brainer. And so where they're assessing it is what is the budget going to be? You know, what's the budget impact? What does financial modeling look like? Adding MROSI, of course. It behooves the GPO to have MROSI on formulary for their plan participants because these are rebate dollars for them. So that helps them, you know, And that helps the system. So that's the way they look at it. And so we do expect incremental growth here on the gross to net. And that's really a function, as Claude mentioned, of reimbursement, which ultimately will put less and less pressure on the copay. But during the launch, of course, you're going to have demand lag, revenue lag. Your demand, we're focused on widestream adoption. The commercial team has done an excellent job with adopters. with new patients, refills, and so on and so forth. Our job is on the back end, really, as you mentioned, that gross to net and optimizing that. Unfortunately, in the ecosystem, we don't really control timing. So from a timing perspective, phase one is nearly complete here with the third to come on board, and really the hard work will continue getting formulary coverage for M-ROSI, and that's where you'll start to see improvement in gross to net in 26 and throughout 27 and beyond.

Thank you. Go ahead.

Mayank, if I can follow up a little bit, too. You know, you're asking for some to quantify a little bit. Look, the run rate annualized out of Q4 is 126,000 prescriptions running into 2026. We certainly expect to be well above that. But, you know, I think it's important to really look at NRXs and TRXs. And the current ratio in Q4 was for every one new prescription, we were getting 1.4 refills. So together, you know, you're at 2.4 per patient. And, you know, our 16-week clinical trials, so there was four months of therapy there. We believe and anticipate that the refill rates will continue to grow with this product. And I'd like you to remember that this is a chronic condition. As fantastic as ambrosia is, it's still not a cure. So patients will get, you know, symptomatic relief. They'll get their clearing, but then they will relapse. and come back and have a flare-up. So the value of each of these new patients that come on in 2025, we're going to get a number of those coming back to us in 2026. It's hard to give you and quantify a number of that, but keep that in mind. And additionally, we are going out there as the field forces on a consistent day-to-day basis, asking for new prescriptions and for these patients that are coming in that are actually new. So it becomes a snowball effect here over time. So time is on our side. Obviously, the long term view, we've got great IP going out to 2039. But in the short term here in 2026, we can already take advantage of that. So those numbers are going to be real important. And right now, we're doing about 4,000 new prescriptions per month on a basis. And we expect that number to rise throughout the year.

Yeah, we're definitely closely following that. And then you mentioned some presentation publications for Enrosi. Any ones we should be particularly paying attention to from a health economic standpoint or, you know, things like durability, even return patients you're seeing in real world that you just alluded to. And finally, you know, these two niche Derm product launches that you talked about, Maybe just, you know, put the picture together on how you're thinking of marketing, you know, overall spend beyond the, you know, the sales rep incremental spend that you talked about, just so we understand how first half versus second half looks like from a bottom line standpoint. Thank you for taking that question.

Sure. Yeah. So regarding the two products that we can potentially launch here, we're definitely seeing one We see that happening in the second half of 2026 here and possibly two. So that's how that outlook is doing. We're calling that part of the base business and, you know, in the base business in 2025, and that's all business outside of Ambrosie. We did about $46 million in revenues. We expect that base business to continue to be stable. We feel like the regression that we saw in Accutane has done its part. That was about $6.5 million or so that we went down in revenues. So all prescriptions are looking strong from Q3 to Q4. It's been stable, and we have good, you know, trends right now with Accutane in Q1 of 2026. So the added product and the launch, we do have expenses already built into our budget. This would be in a P3 position and where we would have pulse promotion with this utilizing our full and entire sales force. We're not taking our eye off of Amrosi. That will be obviously first out of the bag for us in dominating compensation programs for our representatives. The second product will continue to be Q-Brexa followed by the launch product as we introduce it into the marketplace. Not really giving too much details on that just due to competitive reasons. We'll give you more information as we get closer on that, Mayak.

The publication presentation for MROSI?

So, yeah, we're expecting two to three publications, and we're just, those we have to, you know, keep in terms of what those aspects are. They're obviously all about MROSI. but we'll let you know, and we should expect to see at least one of them hit here in the very near future. So we'll give you information as we can.

Okay, thank you. I'll hop back in the queue.

The next question comes from Brandon Foulkes with HC Wainwright. Please go ahead.

Hi, thanks for taking my questions, and congrats on the progress. Maybe the first one from me, Can you just help us understand the inventory movement in MROSI and the broader portfolio in 4Q? I know you talked about the overall working capital balance at year-end, so I'd just be interested in terms of inventory in the channel at year-end across the portfolio. And then I'll ask my same one now, and it sort of tacks onto what's been asked already. How do gross-to-nets now at this stage of the launch compare to your expectations prior to launch? And when, you know, we had talked about and framed peak sales in the past, you know, any way to characterize sort of where you are on the gross to nets now versus how you thought about gross to nets and how they would track before launch. Thank you.

Okay, sure. So we'll take the first part regarding the inventory very much on track with units sold and prescriptions on demand. So that's pretty much across the entire line. So that is well within standards. Then on the second part, you mentioned gross to net and where it's come to our expectations. I think we're on track, certainly. So far today's number is 280 as the average for 2025. That certainly is within line and expectation. So you know, that's certainly meeting our internal expectations. And again, that's what was just mentioned here on the call by another analyst. So that's number one, because we don't typically give out our gross to net numbers. In terms of where we expect our gross to net, right now I would tell you that the expectation moving forward is an increase due to the reimbursement progress that we're going to make with the downstream health care plans. So the expectation is upward pressure as we move forward into 2026. Joe, anything else you'd like to add on that?

No, I think just to expand on what you said, you know, our real goal is to, you know, maximize the gross to net and optimize the gross to net, optimize the margins, and optimize the overproduct contributions from all products, you know, into the EBITDA and adjusted EBITDA numbers. So just, you know, just to expand on what you said.

Yeah. And finally, I think you asked about the peak sales. regarding MROSI. Look, we're very bullish. We see this product as becoming one of the leading branded dermatology products out there in medical therapeutics. This is a ripe target market. 17 million people suffer from this. Well over 6 million prescriptions are being written for this target market on an annual basis. And we're just really getting going here. And our adopter base, in terms of where we ended the year, hitting our target of 32 unique prescribers. You know, we've broken our targets into deciles. We've made some really strong penetration in those, especially the decile 6 through 10. So we feel pretty good about how we're moving along here. And, you know, being added to the Potential guidelines of the National Rosacea Society in the upcoming months, I think, is just more validation for the brand and acceptance. So I think it's looking really positive as we continue to move forward.

Thanks. And one just clarification, if I may. You mentioned upward pressure. Are you talking about net revenue per script going up or gross to net going up?

Yeah, meaning that, you know, as reimbursement goes up, less subsidies from our co-pay assistance program will be utilized, so the profitability of an MRSC script would be going up. Gross-to-net would be going up in a positive manner.

Okay. I appreciate the clarification. Thanks very much, and congrats on the progress. Thank you.

The next question comes from Thomas Flatton. with Lake Street Capital Markets. Please go ahead.

Hey, good afternoon. Appreciate you guys taking the questions. Joe, there was a pretty substantial increase in accounts receivable in the fourth quarter. Is that cash we can expect you to recognize as we go through 26? It was just an unusual number for you guys. Any commentary on that?

Yeah, so really, I can't tell you subsequently. We have collected most but not all of that cash, so it will impact our first quarter. I think it was just more of a timing thing at year end. Nothing major there, just the timing of the orders.

Got it. And then sticking with Joe, as MROSI continues to gain better coverage, GTMs improved, and it becomes a bigger component of your revenue line. How can we think about gross margins as we roll through 26?

Yeah. So, you know, really, really happy with the margins and how they're progressing. You know, of course the product sales mix is always going to be the biggest driver. So as MROSI and CubeRexa are high margin products become more of that mix, you know, we're going to continue to see better, better margins. And in addition, you know, we really try to manage and optimize the period costs that go through, you know, the shipping costs, testing costs, et cetera. So we've made a lot of lead way into decreasing those costs. So looking forward, you know, I expect there's some really nice margins going forward into 2026 and beyond.

Great. And then, Claude, the product launches that you mentioned, are these products you already have in-house? Is it BD on the come product? And anything you can do to characterize, you know, kind of conditions they serve, overall market size that you're addressing, and anything just to give us some more context would be great.

I would look at them as really incremental product additions into the portfolio to really assist in helping the base business. And again, that's defined as everything outside of Amorosi really grow and expand. an internal product that we've been developing, as well as an additional licensing deal. So in terms of the categories, I'll get into that later in the year as we come closer to launch, Thomas. Got it.

Appreciate that. Thanks, guys.

This concludes our question and answer session and Journey Medical's full year 2025 financial results and corporate update conference call. Thank you for attending today's presentation. You may now disconnect.